focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCIN.L Regulatory News (SCIN)

  • There is currently no data for SCIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Bondholder Meeting

29 Jul 2022 10:43

RNS Number : 2667U
Scottish Investment Trust PLC
29 July 2022
 

To: RNS

From: The Scottish Investment Trust PLC

LEI: 549300ZL6XSHQ48U8H53

Date: 29 July 2022

 

FOR DISTRIBUTION ONLY OUTSIDE THE UNITED STATES TO PERSONS OTHER THAN U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION FOR WHICH THE SAME COULD BE UNLAWFUL. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION, INCLUDING IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA.

The Scottish Investment Trust PLC

("SIT" or the "Company")

Results of Bondholder Meeting

in respect of its outstanding £150,000,000 5 ¾ per cent. secured bonds due 2030 (of which £82,827,000 remains outstanding) (ISIN: GB0002616471 / XS0109354075)

(the "Bonds")

 

The Company is pleased to announce that its Bondholders have today given their consent to the substitution of JPMorgan Global Growth & Income plc ("JGGI") in place of the Company as the issuer and sole debtor of the Bonds (the "Substitution") in connection with the proposed combination of the assets of the Company with JGGI by means of a scheme of reconstruction and voluntary winding up of the Company pursuant to section 110 of the Insolvency Act 1986, as amended (the "Transaction").

Background

On 30 June 2022 the Company announced a consent solicitation (the "Consent Solicitation") and convened a meeting of the Bondholders (the "Meeting") to consider and, if thought fit, approve the Substitution and related amendments to the terms of the Bonds and the trust deed constituting the Bonds (the "Trust Deed" and together the "Proposals") by way of an extraordinary resolution (the "Extraordinary Resolution").

The Consent Solicitation was made on the terms, and subject to the conditions, set out in the consent solicitation memorandum (the "Consent Solicitation Memorandum") and the notice of meeting both dated 30 June 2022 and, in particular, the terms of the Substitution Documents. Capitalised terms used but not defined in this announcement have the same meaning given to them in the Consent Solicitation Memorandum.

The Meeting was attended by proxies or persons holding voting certificates representing, in aggregate, approximately 99.76 per cent. in principal amount of the Bonds presently outstanding and the Meeting was therefore quorate in accordance with the terms of the Trust Deed. 

Bondholders representing approximately 89.45 per cent. of the outstanding Bonds voted in favour of the Extraordinary Resolution at the Meeting and the Company hereby gives notice that the Extraordinary Resolution was duly passed by the required majority.

Implementation of the Substitution and the Transaction

As set out in the Consent Solicitation Memorandum, it is intended that the Substitution (including the Substitution Documents) will take effect on the same date as the Transaction. Having received Bondholder consent to the Substitution, the Board of the Company believes that it is now appropriate to move forward with the remainder of the Transaction and the Company will therefore, in conjunction with JGGI, provide further information and documentation to shareholders shortly. 

Subject, inter alia, to the approval of the Transaction by the shareholders of both SIT and JGGI, it is expected that the Substitution and the Transaction will take effect on or around 31 August 2022.

Payment of Revised Instruction Fee

As announced on 26 July 2022, the Board (i) extended the Instruction Fee Deadline under the Consent Solicitation Memorandum to 4.00 p.m. on 26 July 2022 and (ii) increased the Instruction Fee under the Consent Solicitation Memorandum to 0.20 per cent. of the outstanding principal amount of the Bonds held by the relevant Bondholder and which were the subject of the relevant Electronic Voting Instruction or Ineligible Bondholder Instruction (the "Revised Instruction Fee").

It is intended that payment of the Revised Instruction Fee to those Bondholders who are eligible, in accordance with the conditions set out in the Consent Solicitation Memorandum, will be made by SIT on or around 4 August 2022.

Further Information

Any persons with questions regarding the terms of the Proposals or the Consent Solicitation should contact Centrus Financial Advisors Limited ("Centrus") at the addresses or telephone number specified below:

 

Centrus Financial Advisors Limited

85 Queen Victoria Street

London EC4V 4AB

Telephone: +44 (0)20 3846 5676

Attention: Robert St John

Email: robert.stjohn@centrusadvisors.com

 

Centrus is not acting through a U.S. broker-dealer affiliate and, accordingly, will not discuss the Consent Solicitation or the contents of the Consent Solicitation Memorandum or the Notice of Meeting with any Bondholder who is unable to confirm that it is not located or resident in the United States.

Important Information

Within the United Kingdom, this announcement is directed only at persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("relevant persons"). The investment or investment activity to which this announcement relates is only available to and will only be engaged in with relevant persons and persons who receive this announcement who are not relevant persons should not rely or act upon it.

Nothing in this announcement or the Consent Solicitation Memorandum constitutes or forms part of, and should not be construed as, an offer for sale or subscription of, or a solicitation of any offer to buy or subscribe for, any securities of the Company or any other entity. None of the Company, the Trustee, the Tabulation Agent or Centrus Financial Advisers Limited will incur any liability for the failure of any person or persons to comply with the provisions of any such restrictions.

If Bondholders are in any doubt about the action they should take or the contents of this announcement, the Consent Solicitation Memorandum or the Substitution Documents they are recommended to seek their own independent financial advice immediately from their stockbroker, bank manager, solicitor, accountant or other appropriate independent financial adviser who is authorised under the Financial Services and Markets Act 2000 (as amended) if they are in the United Kingdom, or from another appropriately authorised independent financial adviser if they are in a territory outside the United Kingdom.

The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about, and to observe, any such restrictions.

The Bonds have not been, and will not be, registered under the U.S. Securities Act of 1933 (the "Securities Act") or the securities law of any state or jurisdiction of the United States and may not be reoffered or resold except pursuant to an applicable exemption from the registration requirements of the Securities Act. Neither the SEC nor any U.S. state securities commission has approved or disapproved of any Bonds, or determined if the Consent Solicitation Memorandum is accurate or complete. Any representation to the contrary is a criminal offence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMDZGZNLLZGZZG
Date   Source Headline
14th Jul 202210:23 amRNSNet Asset Value(s)
13th Jul 202210:32 amRNSNet Asset Value(s)
12th Jul 20221:38 pmRNSTen Largest Investments
12th Jul 202210:20 amRNSNet Asset Value(s)
11th Jul 20225:02 pmRNSDirector Declaration
11th Jul 202211:17 amRNSGearing announcement
11th Jul 202211:07 amRNSNet Asset Value(s)
8th Jul 202210:29 amRNSNet Asset Value(s)
7th Jul 202211:04 amRNSNet Asset Value(s)
6th Jul 202210:52 amRNSNet Asset Value(s)
5th Jul 202210:37 amRNSNet Asset Value(s)
4th Jul 202212:53 pmRNSGearing Announcement
4th Jul 202211:24 amRNSNet Asset Value(s)
1st Jul 202210:52 amRNSNet Asset Value(s)
30th Jun 20223:52 pmRNSHalf-year Report
30th Jun 20222:51 pmRNSConsent Solicitation and Bondholder Meeting Notice
30th Jun 202210:50 amRNSNet Asset Value(s)
29th Jun 202210:37 amRNSNet Asset Value(s)
28th Jun 202210:26 amRNSNet Asset Value(s)
27th Jun 20221:58 pmRNSGearing Announcement
27th Jun 202210:59 amRNSNet Asset Value(s)
24th Jun 202211:19 amRNSNet Asset Value(s)
23rd Jun 202210:44 amRNSNet Asset Value(s)
22nd Jun 202210:46 amRNSNet Asset Value(s)
21st Jun 202210:29 amRNSNet Asset Value(s)
20th Jun 202211:45 amRNSGearing Announcement
20th Jun 202211:08 amRNSNet Asset Value(s)
17th Jun 202211:34 amRNSTen Largest Investments
17th Jun 202210:47 amRNSNet Asset Value(s)
16th Jun 202210:43 amRNSNet Asset Value(s)
15th Jun 20223:12 pmRNSDividend Declaration
15th Jun 202210:44 amRNSNet Asset Value(s)
14th Jun 202210:54 amRNSNet Asset Value(s)
13th Jun 202211:47 amRNSGearing Announcement
13th Jun 202210:36 amRNSNet Asset Value(s)
10th Jun 202211:09 amRNSNet Asset Value(s)
9th Jun 202211:01 amRNSNet Asset Value(s)
8th Jun 202210:44 amRNSNet Asset Value(s)
7th Jun 202211:20 amRNSNet Asset Value(s)
6th Jun 202212:59 pmRNSGearing Announcement
6th Jun 202212:30 pmRNSNet Asset Value(s)
1st Jun 202210:47 amRNSNet Asset Value(s)
31st May 202210:34 amRNSNet Asset Value(s)
30th May 202211:48 amRNSGearing Announcement
30th May 202211:08 amRNSNet Asset Value(s)
27th May 202211:05 amRNSNet Asset Value(s)
26th May 202210:33 amRNSNet Asset Value(s)
25th May 202210:36 amRNSNet Asset Value(s)
24th May 202210:30 amRNSNet Asset Value(s)
23rd May 202211:12 amRNSGearing Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.